This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chresta, C. M. Articles by Hickman, J. A. Search for Related Content PubMed PubMed Citation Articles by Chresta, C. M. Articles by Hickman, J. A.

Hypersensitivity of Human Testicular Tumors to Etoposide-induced Apoptosis Is Associated with Functional p53 and a High Bax:Bcl-2 Ratio¹

Cancer Research Campaign Molecular and Cellular Pharmacology Research Group, School of Biological Sciences, The University of Manchester, G.38. Stopford Building, Oxford Road, Manchester, M13 9PT [C. M. C., J. A. H.], and Institute of Urology and Nephrology, University College London, 67 Riding House Street, London, W1P 7PN [J. R. W. M.], United Kingdom

Metastatic testicular cancers are curable, whereas bladder cancers and most other solid tumors are not. Cell lines derived from human testicular (GH, GCT27, and 833K) and bladder (RT4, RT112, and HT1376) tumors retain this differential chemosensitivity in vitro. We have investigated the hypothesis that differential sensitivity to chemotherapy is related to differences in the threshold of susceptibility to undergoing apoptosis. Sensitivity to etoposide was not directly related to the frequency of DNA strand breaks. DNA damage was on average 2-fold greater in the testicular than the bladder tumor cell lines; in contrast, the testicular tumor lines were 15-fold more sensitive to etoposide cytotoxicity than the bladder tumor lines (IC₉₀ values of 19 ± 6 versus 293 ± 180 µM, respectively). Using equidamaging (550 rad equivalents) etoposide treatments, the percentage of cells that underwent drug-induced apoptosis was on average higher in the testicular tumor cell lines than the bladder tumor cell lines. The testicular tumor lines have two characteristics that could confer sensitivity to drug-induced apoptosis. First, they have functional p53: the product of the p53-dependent gene waf-1 was increased after etoposide treatment. Second, the testicular tumor lines expressed relatively high levels of the apoptosis-promoting protein Bax, but there was no expression of the suppressor of apoptosis Bcl-2. In contrast, only one of the three bladder cell lines (RT4) had functional p53, and all of the bladder lines had readily detectable levels of Bcl-2 and low levels of Bax. In the testicular cell lines, increases in p53 and p53-transactivated genes were associated with apoptosis but not arrest in G₁. In contrast, in the bladder cell line (RT4), increases in p53 and Waf-1 were associated with both arrest in G₁ and apoptosis. The differences in the ratio of Bax:Bcl-2 could contribute to the differential sensitivity of the two tumor types. However, in contrast to earlier reports, the ratio of Bax and Bcl-2 was not perturbed by DNA damage.

¹ Supported by Project Grant SP2234 from the Cancer Research Campaign (to C. M. C.).

² To whom requests for reprints should be addressed. Fax: 0161-275-5500.

Received 7/26/95. Accepted 2/15/96.

This article has been cited by other articles:

				F.-T. Liu, S. G. Agrawal, J. G. Gribben, H. Ye, M.-Q. Du, A. C. Newland, and L. Jia Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL Blood, March 1, 2008; 111(5): 2797 - 2805. [Abstract] [Full Text] [PDF]

				F. Vaisheva, G. Delbes, B. F. Hales, and B. Robaire Effects of the Chemotherapeutic Agents for Non-Hodgkin Lymphoma, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), on the Male Rat Reproductive System and Progeny Outcome J Androl, July 1, 2007; 28(4): 578 - 587. [Abstract] [Full Text] [PDF]

				G.-S. Shieh, A.-L. Shiau, Y.-T. Yo, P.-R. Lin, C.-C. Chang, T.-S. Tzai, and C.-L. Wu Low-Dose Etoposide Enhances Telomerase-Dependent Adenovirus-Mediated Cytosine Deaminase Gene Therapy through Augmentation of Adenoviral Infection and Transgene Expression in a Syngeneic Bladder Tumor Model. Cancer Res., October 15, 2006; 66(20): 9957 - 9966. [Abstract] [Full Text] [PDF]

				S. Saeed, C. A. Keehn, F. K Khalil, and M. B. Morgan Immunohistochemical Expression of Bax and Bcl-2 in Penile Carcinoma Ann. Clin. Lab. Sci., January 1, 2005; 35(1): 91 - 96. [Abstract] [Full Text] [PDF]

				F. Mayer, F. Honecker, L. H. J. Looijenga, and C. Bokemeyer Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors Ann. Onc., June 1, 2003; 14(6): 825 - 832. [Abstract] [Full Text] [PDF]

				F. Mayer, H. Stoop, G. L. Scheffer, R. Scheper, J. W. Oosterhuis, L. H. J. Looijenga, and C. Bokemeyer Molecular Determinants of Treatment Response in Human Germ Cell Tumors Clin. Cancer Res., February 1, 2003; 9(2): 767 - 773. [Abstract] [Full Text] [PDF]

				T. Mueller, W. Voigt, H. Simon, A. Fruehauf, A. Bulankin, A. Grothey, and H.-J. Schmoll Failure of Activation of Caspase-9 Induces a Higher Threshold for Apoptosis and Cisplatin Resistance in Testicular Cancer Cancer Res., January 15, 2003; 63(2): 513 - 521. [Abstract] [Full Text] [PDF]

				D. G. B. Leonard, L. B. Travis, K. Addya, G. M. Dores, E. J. Holowaty, K. Bergfeldt, D. Malkin, B. A. Kohler, C. F. Lynch, T. Wiklund, et al. p53 Mutations in Leukemia and Myelodysplastic Syndrome after Ovarian Cancer Clin. Cancer Res., May 1, 2002; 8(5): 973 - 985. [Abstract] [Full Text] [PDF]

				A. M. Rodriguez-Lopez, D. Xenaki, T. O. B. Eden, J. A. Hickman, and C. M. Chresta MDM2 Mediated Nuclear Exclusion of p53 Attenuates Etoposide-Induced Apoptosis in Neuroblastoma Cells Mol. Pharmacol., January 1, 2001; 59(1): 135 - 143. [Abstract] [Full Text]

				M. Watabe, H. Kakeya, R. Onose, and H. Osada Activation of MST/Krs and c-Jun N-terminal Kinases by Different Signaling Pathways during Cytotrienin A-induced Apoptosis J. Biol. Chem., March 17, 2000; 275(12): 8766 - 8771. [Abstract] [Full Text] [PDF]

				R. S. K. Chaganti and J. Houldsworth Genetics and Biology of Adult Human Male Germ Cell Tumors Cancer Res., March 1, 2000; 60(6): 1475 - 1482. [Abstract] [Full Text]

				D. Schwartz, N. Goldfinger, Z. Kam, and V. Rotter p53 Controls Low DNA Damage-dependent Premeiotic Checkpoint and Facilitates DNA Repair during Spermatogenesis Cell Growth Differ., October 1, 1999; 10(10): 665 - 675. [Abstract] [Full Text]

				G.-J. Zhang, I. Kimijima, M. Onda, M. Kanno, H. Sato, T. Watanabe, A. Tsuchiya, R. Abe, and S. Takenoshita Tamoxifen-induced Apoptosis in Breast Cancer Cells Relates to Down-Regulation of bcl-2, but not bax and bcl-XL, without Alteration of p53 Protein Levels Clin. Cancer Res., October 1, 1999; 5(10): 2971 - 2977. [Abstract] [Full Text] [PDF]

				M. Kusumoto, T. Ogawa, K. Mizumoto, H. Ueno, H. Niiyama, N. Sato, M. Nakamura, and M. Tanaka Adenovirus-mediated p53 Gene Transduction Inhibits Telomerase Activity Independent of Its Effects on Cell Cycle Arrest and Apoptosis in Human Pancreatic Cancer Cells Clin. Cancer Res., August 1, 1999; 5(8): 2140 - 2147. [Abstract] [Full Text] [PDF]

				A. Niero, E. Emiliani, G. Monti, F. Pironi, L. Turci, A. M. Valenti, and M. Marangolo Paclitaxel and Radiotherapy: Sequence-dependent Efficacy--A Preclinical Model Clin. Cancer Res., August 1, 1999; 5(8): 2213 - 2222. [Abstract] [Full Text] [PDF]

				G. J. Griffiths, L. Dubrez, C. P. Morgan, N. A. Jones, J. Whitehouse, B. M. Corfe, C. Dive, and J. A. Hickman Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis J. Cell Biol., March 8, 1999; 144(5): 903 - 914. [Abstract] [Full Text] [PDF]

				H.-M. Koo, M. Gray-Goodrich, G. Kohlhagen, M. J. McWilliams, M. Jeffers, A. Vaigro-Wolff, W. G. Alvord, A. Monks, K. D. Paull, Y. Pommier, et al. The ras Oncogene-Mediated Sensitization of Human Cells to Topoisomerase II Inhibitor-Induced Apoptosis J Natl Cancer Inst, February 3, 1999; 91(3): 236 - 244. [Abstract] [Full Text] [PDF]

				E. Willmore, A. J. Frank, K. Padget, M. J. Tilby, and C. A. Austin Etoposide Targets Topoisomerase IIalpha and IIbeta in Leukemic Cells: Isoform-Specific Cleavable Complexes Visualized and Quantified In Situ by a Novel Immunofluorescence Technique Mol. Pharmacol., July 1, 1998; 54(1): 78 - 85. [Abstract] [Full Text]

				S. R. Narasimhan, L. Yang, B. I. Gerwin, and V. C. Broaddus Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax Am J Physiol Lung Cell Mol Physiol, July 1, 1998; 275(1): L165 - L171. [Abstract] [Full Text] [PDF]

				D. B. Zamble, T. Jacks, and S. J. Lippard p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells PNAS, May 26, 1998; 95(11): 6163 - 6168. [Abstract] [Full Text] [PDF]

				M. Wu, R. E. Bellas, J. Shen, and G. E. Sonenshein Roles of the Tumor Suppressor p53 and the Cyclin-dependent Kinase Inhibitor p21WAF1/CIP1 in Receptor-mediated Apoptosis of WEHI 231 B Lymphoma Cells J. Exp. Med., May 18, 1998; 187(10): 1671 - 1679. [Abstract] [Full Text] [PDF]

				D.R. Richardson and K. Milnes The Potential of Iron Chelators of the Pyridoxal Isonicotinoyl Hydrazone Class as Effective Antiproliferative Agents II: The Mechanism of Action of Ligands Derived From Salicylaldehyde Benzoyl Hydrazone and 2-Hydroxy-1-Naphthylaldehyde Benzoyl Hydrazone Blood, April 15, 1997; 89(8): 3025 - 3038. [Abstract] [Full Text] [PDF]

				A. J. Muller, A. K. Teresky, and A. J. Levine A male germ cell tumor-susceptibility-determining locus, pgct1, identified on murine chromosome 13 PNAS, July 18, 2000; 97(15): 8421 - 8426. [Abstract] [Full Text] [PDF]